We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Smith & Nephew Plc | LSE:SN. | London | Ordinary Share | GB0009223206 | ORD USD0.20 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 5.50 | 0.51% | 1,079.50 | 4,371,260 | 16:35:28 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1,077.00 | 1,078.00 | 1,089.00 | 1,075.00 | 1,077.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Ortho,prosth,surg Appl,suply | USD 5.81B | USD 412M | USD 0.4703 | 22.91 | 9.41B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:47:02 | O | 41 | 1,023.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/6/2025 | 09:00 | UKREG | Smith+Nephew and Standard Health partner on first Orthopaedic Ambulatory.. |
| 13/6/2025 | 07:00 | UK RNS | Smith & Nephew Plc Directorate Change |
| 09/6/2025 | 15:00 | UKREG | New medial stabilized insert for Smith+Nephew’s LEGION™ Total Knee System.. |
| 06/6/2025 | 16:16 | UK RNS | Smith & Nephew Plc Director/PDMR Shareholding |
| 02/6/2025 | 14:07 | UK RNS | Smith & Nephew Plc Total Voting Rights |
| 30/5/2025 | 13:22 | UK RNS | Smith & Nephew Plc Director/PDMR Shareholding |
| 27/5/2025 | 18:16 | ALNC |  IN BRIEF: Smith & Nephew inks 10-year contract with US government |
| 27/5/2025 | 15:00 | UKREG | Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy.. |
| 21/5/2025 | 15:00 | UK RNS | Smith & Nephew Plc Director/PDMR Shareholding |
| 14/5/2025 | 13:00 | UKREG | A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces.. |
Smith & Nephew (SN.) Share Charts1 Year Smith & Nephew Chart |
|
1 Month Smith & Nephew Chart |
Intraday Smith & Nephew Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 30/4/2025 | 14:25 | *** Smith and Nephew *** | 827 |
| 29/10/2015 | 08:48 | SN. | 122 |
| 10/1/2011 | 13:03 | Smith and Nephew 2008 | 67 |
| 09/1/2011 | 17:12 | Smiths: Charts and News etc. | 296 |
| 25/9/2006 | 15:09 | Smith&Nep. Why the rise? | 75 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 22/6/2025 09:20 by Smith & Nephew Daily Update Smith & Nephew Plc is listed in the Ortho,prosth,surg Appl,suply sector of the London Stock Exchange with ticker SN.. The last closing price for Smith & Nephew was 1,074p.Smith & Nephew currently has 875,945,333 shares in issue. The market capitalisation of Smith & Nephew is £9,438,310,963. Smith & Nephew has a price to earnings ratio (PE ratio) of 22.91. This morning SN. shares opened at 1,077p |
Posted at 25/2/2025 10:59 by martinmc123 wealthoracle.co.uk/d |
Posted at 11/12/2024 20:06 by justiceforthemany You guys with stakes here need to be proactive....contact the hierarchy and major institutional investors.Deepak is also on LinkedIn. This is trading at half what it would if listed on a fair and regulated exchange that is not infested with short sellers. Stryker trades at a 40x P/E! More than double that of SN. |
Posted at 14/11/2024 07:33 by foreverbull FT article Big investors call for break-up of Smith & NephewThree top 20 shareholders say medical devices company should consider spinning off orthopaedics unitSmith and Nephew logoThe UK-headquartered company has been urged to spin off its orthopaedics division © DreamstimeThree major investors are pushing FTSE 100 company Smith & Nephew to consider a break-up of the business, after disappointing results last month reignited concerns about the medical device maker's strategy.The top 20 shareholders told the Financial Times that the UK-headquartered company should spin off its orthopaedics division, which makes replacement hip and knee joints, if management could not improve its performance.Two of the investors said that a private equity firm could be a potential buyer for the division, the largest by sales of the company's three business lines. "If they could find a buyer for the orthopaedic business that would be quite compelling," one of the investors said.Shares in Smith & Nephew have fallen more than 13 per cent since the end of October when it cut its growth forecast for the year, citing poor sales in China linked to changes in the country's procurement policies. It also said it would continue to struggle in 2025.But China accounted for just 5 per cent of sales last year according to its annual report, and investors said the challenges were more widespread, including a loss of market share in the US, where it makes the majority of its sales.Rupert Soames, chair of Smith & Nephew, told the Financial Times: "We have a well-formed strategy and a plan that we are diligently executing?.?.?.?it encompasses all three of our business lines."Swedish activist Cevian took a 5 per cent stake in the company earlier this year, saying it "owns fundamentally attractive businesses", but had failed to create shareholder value.Its shares are down more than 40 per cent over the past five years as it has struggled with high turnover of executives and underperformance in its orthopaedics division.Orthopaedic |
Posted at 06/11/2024 12:13 by uhound SN. Price target cut to £10.50 by Berenberg.However, some would say this is now offering very good value. |
Posted at 05/11/2024 00:24 by philanderer On Monday, Canaccord Genuity adjusted its outlook for medical equipment manufacturer Smith & Nephew (NYSE: SNN), reducing the price target from $32.00 to $27.00 while keeping a Hold rating on the stock.(Two ordinary shares of Smith & Nephew (SN) are represented by one American Depositary Share (ADR). |
Posted at 05/11/2024 00:16 by philanderer Jefferies cuts Smith & Nephew target but stays optimisticJefferies has slashed its target price for medical devices maker Smith & Nephew from 1,400p to 1,250p after challenges in China weighed heavily on third-quarter results. Nevertheless, the broker kept a 'buy' rating on the stock, saying that the shares' valuation is undemanding by historical standards. Smith & Nephew reported on Thursday that it was cutting its 2024 and 2025 guidance on the back of struggles in China, where it was impacted by worse-than-expected headwinds across the surgical businesses. "This is a clear step back as investors were slowly starting to reward management for improved visibility and consistency," Jefferies said in a research note on Monday. "While unhelpful, China setbacks seem temporary and SN is slowly reaping the benefits from portfolio shifting toward faster-growth segments and recent R&D efforts, which support higher, sustainable growth." The stock has dropped by around 20% over the past three months, leaving its close to an all-time low price-to-earnings ratio of just 12.5. Jefferies said it sees "ample room for [a] re-rating". Sharecast |
Posted at 31/10/2024 13:02 by ricardo montalban Back to the same price as 2013, U.K. indexes really are a black hole for capital destruction. |
Posted at 31/10/2024 10:02 by essentialinvestor SN has had a succession of CEO's over the last decade, each with a different action plan, areas of focus, yet the result has been similar - early promise followed by disappointment.A bid may be the best hope. The balance sheet, once rock solid, has been geared through acquisitions. |
Posted at 25/10/2024 12:05 by suetballs This share keeps on disappointing.Fed up after many years of holding. Suet |
Posted at 30/4/2024 05:17 by alotto Smith and nephew has always been way overpriced. Even at the current level still seems overpriced. The dividend payout is below what you get from a saving account and the prospect for growth is just about meh.The share price should be half as much to yield a healthy dividend of 5-6%. I would buy only with the wish of seeing the share price back to historical levels but I can't put any weight behind my wish especially with the debt it carries and the rates. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
